 | MHRA Drug Safety Update April 2022.pdf (262KB) | 25/04/2022 | Download |
| | |
 | MHRA Drug Safety Update March-2022-DSU-PDF.pdf (420KB) | 15/03/2022 | Download |
| Cladribine (Mavenclad): new advice to minimise risk of serious liver injury, Amiodarone (Cordarone X): reminder of risks of treatment and need for patient monitoring and supervision, Metformin in... | |
 | Drug Safety Update February -2022-_PDF.pdf (363KB) | 15/02/2022 | Download |
| | |
 | Drug Safety Update January -2022-_PDF.pdf (247KB) | 19/01/2022 | Download |
| | |
 | Drug Safety Update December 2020-DSU-PDF-1712.pdf (263KB) | 10/12/2021 | Download |
| Haloperidol (Haldol): reminder of risks when used in elderly patients for the acute treatment of delirium. Venetoclax (Venclyxto▼): updated recommendations on tumour lysis syndrome (TLS).... | |
 | Drug Safety Update MHRA November -2021-PDF.pdf (257KB) | 17/11/2021 | Download |
| Yellow fever vaccine (Stamaril): new pre-vaccination checklist. Adrenaline auto-injectors: reminder for prescribers to support safe and effective use . | |
 | Drug Safety Update MHRA October 2021-PDF.pdf (287KB) | 07/10/2021 | Download |
| Tofacitinib (Xeljanz▼): new measures to minimise risk of major adverse cardiovascular events and malignancies page 2 Chloral hydrate, cloral betaine (Welldorm): restriction of paediatric indication... | |
 | Drug safety Update MHRA Sept-2021-DSU-PDF.pdf (208KB) | 15/09/2021 | Download |
| Topical corticosteroids: information on the risk of topical steroid withdrawal reactions. COVID-19 vaccines and medicines: updates for August 2021. | |
 | Drug Safety Update MHRA August -2021-DSU-PDF.pdf (179KB) | 31/08/2021 | Download |
| | |
 | Drug Safety Update MHRA July-2021-DSU-PDF.pdf (280KB) | 08/07/2021 | Download |
| Chloramphenicol eye drops containing borax or boric acid buffers: use in children younger than 2 years . Herbal and homeopathic medicines: reminder to be vigilant for suspected adverse reactions... | |
 | Drug Safety Update MHRA June-2021-DSU-PDF.pdf (226KB) | 17/06/2021 | Download |
| CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases. Atezolizumab (Tecentriq▼) and other immune-stimulatory... | |
 | Drug Safety Update MHRA May-2021-DSU-PDF.pdf (192KB) | 19/05/2021 | Download |
| Levothyroxine: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products. COVID-19 vaccines: updates for May 2021. | |